ORAFLEX MAY HAVE COMPASSIONATE USE, FDA ACTING COM. NOVITCH TELLS REP. WEISS; FDA REVISING GUIDELINES TO REQUIRE TWO-SPECIES CARCINOGENICITY STUDIES FOR NDA APPROVAL